NO2118279T3 - - Google Patents

Info

Publication number
NO2118279T3
NO2118279T3 NO08727718A NO08727718A NO2118279T3 NO 2118279 T3 NO2118279 T3 NO 2118279T3 NO 08727718 A NO08727718 A NO 08727718A NO 08727718 A NO08727718 A NO 08727718A NO 2118279 T3 NO2118279 T3 NO 2118279T3
Authority
NO
Norway
Application number
NO08727718A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2118279T3 publication Critical patent/NO2118279T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO08727718A 2007-01-16 2008-01-16 NO2118279T3 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88521207P 2007-01-16 2007-01-16
PCT/US2008/051123 WO2008089212A1 (en) 2007-01-16 2008-01-16 Novel composition for treating metabolic syndrome

Publications (1)

Publication Number Publication Date
NO2118279T3 true NO2118279T3 (ja) 2018-04-21

Family

ID=39636359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08727718A NO2118279T3 (ja) 2007-01-16 2008-01-16

Country Status (22)

Country Link
US (1) US8431552B2 (ja)
EP (2) EP2118279B1 (ja)
JP (1) JP5271918B2 (ja)
KR (1) KR101460820B1 (ja)
CN (1) CN101631859B (ja)
AR (1) AR065837A1 (ja)
AU (1) AU2008206328B2 (ja)
BR (1) BRPI0806774A2 (ja)
CA (1) CA2675638C (ja)
DK (1) DK2118279T3 (ja)
ES (1) ES2660173T3 (ja)
IL (1) IL199903A (ja)
MX (1) MX2009007720A (ja)
MY (1) MY154869A (ja)
NO (1) NO2118279T3 (ja)
NZ (1) NZ578891A (ja)
RU (1) RU2486902C2 (ja)
SG (1) SG178716A1 (ja)
TR (1) TR201802359T4 (ja)
TW (2) TWI440456B (ja)
WO (1) WO2008089212A1 (ja)
ZA (1) ZA200904972B (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041643A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
CA2724023C (en) * 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
WO2010053949A1 (en) * 2008-11-04 2010-05-14 Metaproteomics, Llc Phytochemical compositions and methods for activating amp-kinase
KR100922519B1 (ko) * 2008-11-12 2009-10-20 대원제약주식회사 펠루비프로펜을 함유하는 용출률 및 안정성이 개선된 경구투여용 약제학적 제제
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
CA2755069A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
EP2408434A4 (en) * 2009-03-16 2013-11-27 Ipintl Llc TREATMENT OF ALZHEIMER'S DISEASE AND OSTEOPOROSIS AND REDUCTION OF AGING
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
WO2013012760A1 (en) 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CA2872012C (en) * 2012-05-08 2017-06-20 Aeromics, Llc New methods
US20140024708A1 (en) * 2012-07-17 2014-01-23 Banavara L. Mylari Ursolic acid salts for treating diabetes and obesity
US9636329B2 (en) * 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
RS57813B1 (sr) * 2013-03-13 2018-12-31 Hoffmann La Roche Formulacije sa smanjenom oksidacijom
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
CN105636438A (zh) * 2013-03-15 2016-06-01 陈建宏 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
SG11201604153UA (en) 2013-11-06 2016-07-28 Aeromics Inc Novel formulations
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
MY181685A (en) 2014-05-05 2020-12-31 Univ Texas Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US20180228818A1 (en) * 2014-10-01 2018-08-16 Chien-Hung Chen Pharmaceutical composition comprising asprin, metformin, and serotonin with non-ionic surfactant
US10875844B2 (en) 2015-03-04 2020-12-29 Dana-Farber Cancer Institute, Inc. Salicylate inhibitors of MELK and methods of use
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
CN115884790A (zh) * 2020-01-10 2023-03-31 康圣博施医药有限公司 药物的治疗组合以及其使用方法
US20220133700A1 (en) * 2020-10-29 2022-05-05 Thomas Winston Compositions and methods for treating neurological disorders
CN115703772A (zh) * 2021-08-09 2023-02-17 天地恒一制药股份有限公司 艾拉莫德共晶，及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
DE4409411A1 (de) * 1994-03-18 1995-09-28 Oped Gmbh Orthopaedische Produ Verpackungsbehälter
EP0692252B1 (en) * 1994-06-14 2001-04-04 "Raffinerie Tirlemontoise", société anonyme: Use of a composition containing inulin or oligofructose in cancer treatment
DE9414065U1 (de) 1994-08-31 1994-11-03 Roehm Gmbh Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
PL351963A1 (en) 1999-03-19 2003-07-14 Knoll Gmbh Method of treating eating disorders
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
DE19949319A1 (de) 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
EP1097716A1 (en) * 1999-11-03 2001-05-09 Chronolife Inc. Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (TRH)
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
GB0004003D0 (en) 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
ATE305933T1 (de) 2000-07-31 2005-10-15 Hoffmann La Roche Piperazin derivate
YU8803A (sh) * 2000-08-07 2006-01-16 Ranbaxy Signature L.L.C. Tečni oblik metformina
DE60135239D1 (de) 2000-10-16 2008-09-18 Vernalis Res Ltd Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2002038141A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
AU2002224266B2 (en) 2000-11-20 2007-05-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
EP1337518B1 (en) 2000-11-20 2009-06-17 Biovitrum AB (publ) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
WO2002051844A1 (en) 2000-12-27 2002-07-04 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
US20020137787A1 (en) * 2001-03-21 2002-09-26 Geho W. Blair Prevention or treatment of complications related to non-insulin dependent diabetes mellitus or type 2 diabetes mellitus
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1302465A1 (en) 2001-10-11 2003-04-16 BRACCO IMAGING S.p.A. Enhanced substrate imaging by reversible binding to a paramagnetic complex
WO2004009017A2 (en) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
EP1558220B1 (en) * 2003-07-24 2010-02-10 Wockhardt Limited Oral compositions for treatment of diabetes
US20050054731A1 (en) 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060040980A1 (en) * 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
EP1789030A2 (en) 2004-08-30 2007-05-30 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2614664A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome
EP2404604B1 (en) * 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
CA2637027A1 (en) * 2006-01-10 2007-07-19 Ruey J. Yu N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
KR20080085213A (ko) 2006-01-12 2008-09-23 노파르티스 아게 Ｍｔｏｒ 억제제 및 항엽산 화합물의 조합물
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases

Also Published As

Publication number Publication date
NZ578891A (en) 2012-03-30
EP2494967A1 (en) 2012-09-05
CN101631859B (zh) 2017-10-13
RU2486902C2 (ru) 2013-07-10
TWI440456B (zh) 2014-06-11
TR201802359T4 (tr) 2018-03-21
AR065837A1 (es) 2009-07-08
JP2010516689A (ja) 2010-05-20
JP5271918B2 (ja) 2013-08-21
US8431552B2 (en) 2013-04-30
DK2118279T3 (en) 2018-02-26
EP2118279A4 (en) 2010-04-14
IL199903A (en) 2016-06-30
MY154869A (en) 2015-08-14
WO2008089212A1 (en) 2008-07-24
AU2008206328A1 (en) 2008-07-24
RU2009131065A (ru) 2011-02-27
MX2009007720A (es) 2013-03-22
TW200836715A (en) 2008-09-16
TW201433315A (zh) 2014-09-01
KR20090111323A (ko) 2009-10-26
EP2118279B1 (en) 2017-11-22
IL199903A0 (en) 2010-04-15
SG178716A1 (en) 2012-03-29
AU2008206328B2 (en) 2013-10-31
EP2118279A1 (en) 2009-11-18
KR101460820B1 (ko) 2014-11-11
CN101631859A (zh) 2010-01-20
US20080176822A1 (en) 2008-07-24
CA2675638A1 (en) 2008-07-24
BRPI0806774A2 (pt) 2011-09-13
CA2675638C (en) 2015-11-24
ZA200904972B (en) 2010-09-29
ES2660173T3 (es) 2018-03-21
TWI629058B (zh) 2018-07-11

Similar Documents

Publication Publication Date Title
CN300726577S (zh) 枕套(豆蔻年华)
CN300728365S (zh) 手电筒(ksl-0527)
CN300730341S (zh) 挂签(原浆经典挂签)
CN300728161S (zh) 刀闸阀(无凹槽)
CN300726614S (zh) 盘子(俏佳人)
CN300728490S (zh) 宠物屋
CN300728675S (zh) 旅行包(11)
CN300728872S (zh) 椅子(25)
CN300728920S (zh) 餐台(ct838)
CN300730360S (zh) 店牌
CN300729006S (zh) 随车车载通用衣架
CN300729151S (zh) 汤锅(直身4)
CN300730353S (zh) 标帖(火腿午餐肉)
CN300727858S (zh) 圆珠笔(社军1)
CN300729240S (zh) 手柄(锯架2)
CN300726687S (zh) 晒物架(旦型3)
CN300729435S (zh) 包装盒(百奇荔枝风味12盒装)
CN300729519S (zh) 包装盒(新快步)
CN300730801S (zh) 蜡烛(14)
CN300729574S (zh) 饼干包装袋(奶香酥)
CN300729626S (zh) 吊卡
CN300727856S (zh) 笔(k38)
CN300729707S (zh) 首饰链(hy-an0043)
CN300726100S (zh) 扇托(2)
CN300728321S (zh) 隐形纱窗附框